Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer

Alterations in glutamine and beta-alanine metabolism

Jan Budczies, Scarlet F. Brockmöller, Berit M. Müller, Dinesh K. Barupal, Christiane Richter-Ehrenstein, Anke Kleine-Tebbe, Julian L. Griffin, Matej Orešič, Manfred Dietel, Carsten Denkert, Oliver Fiehn

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Molecular subtyping of breast cancer is necessary for therapy selection and mandatory for all breast cancer patients. Metabolic alterations are considered a hallmark of cancer and several metabolic drugs are currently being investigated in clinical trials. However, the dependence of metabolic alterations on breast cancer subtypes has not been investigated on -omics scale. Thus, 204 estrogen receptor positive (ER+) and 67 estrogen receptor negative (ER-) breast cancer tissues were investigated using GC-TOFMS based metabolomics. 19 metabolites were detected as altered in a predefined training set (2/3 of tumors) and could be validated in a predefined validation set (1/3 of tumors). The metabolite changes included increases in beta-alanine, 2-hydroyglutarate, glutamate, xanthine and decreases in glutamine in the ER- subtype. Beta-alanine demonstrated the strongest change between ER- and ER+ breast cancer (fold change = 2.4, p = 1.5E. -20). In a correlation analysis with genome-wide expression data in a subcohort of 154 tumors, we found a strong negative correlation (Spearman R = -0.62) between beta-alanine and 4-aminobutyrate aminotransferase (ABAT). Immunohistological analysis confirmed down-regulation of the ABAT protein in ER- breast cancer. In a Kaplan-Meier analysis of a large external expression data set, the ABAT transcript was demonstrated to be a positive prognostic marker for breast cancer (HR = 0.6, p=3.2E-15). Biological significance: It is well-known for more than a decade that breast cancer exhibits distinct gene expression patterns depending on the molecular subtype defined by estrogen receptor (ER) and HER2 status. Here, we show that breast cancer exhibits distinct metabolomics patterns depending on ER status. Our observation supports the current view of ER+ breast cancer and ER- breast as different diseases requiring different treatment strategies.Metabolic drugs for cancer including glutaminase inhibitors are currently under development and tested in clinical trials. We found glutamate enriched and glutamine reduced in ER- breast cancer compared to ER+ breast cancer and compared to normal breast tissues. Thus, metabolomics analysis highlights the ER- subtype as a preferential target for glutaminase inhibitors.For the first time, we report on a regulation of beta-alanine catabolism in cancer. In breast cancer, ABAT transcript expression was variable and correlated with ER status. Low ABAT transcript expression was associated with low ABAT protein expression and high beta-alanine concentration. In a large external microarray cohort, low ABAT expression shortened recurrence-free survival in breast cancer, ER+ breast cancer and ER- breast cancer.

Original languageEnglish (US)
Pages (from-to)279-288
Number of pages10
JournalJournal of Proteomics
Volume94
DOIs
StatePublished - Dec 6 2013

Fingerprint

beta-Alanine
Metabolomics
Glutamine
Metabolism
Estrogen Receptors
Breast Neoplasms
4-Aminobutyrate Transaminase
Glutaminase
Neoplasms
Tumors
Metabolites
Glutamic Acid
Breast
Clinical Trials
Tissue
Xanthine
Kaplan-Meier Estimate

Keywords

  • ABAT
  • Beta-alanine
  • Breast cancer
  • GABA transaminase
  • Hormone receptor status
  • Metabolomics

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

Budczies, J., Brockmöller, S. F., Müller, B. M., Barupal, D. K., Richter-Ehrenstein, C., Kleine-Tebbe, A., ... Fiehn, O. (2013). Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: Alterations in glutamine and beta-alanine metabolism. Journal of Proteomics, 94, 279-288. https://doi.org/10.1016/j.jprot.2013.10.002

Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer : Alterations in glutamine and beta-alanine metabolism. / Budczies, Jan; Brockmöller, Scarlet F.; Müller, Berit M.; Barupal, Dinesh K.; Richter-Ehrenstein, Christiane; Kleine-Tebbe, Anke; Griffin, Julian L.; Orešič, Matej; Dietel, Manfred; Denkert, Carsten; Fiehn, Oliver.

In: Journal of Proteomics, Vol. 94, 06.12.2013, p. 279-288.

Research output: Contribution to journalArticle

Budczies, J, Brockmöller, SF, Müller, BM, Barupal, DK, Richter-Ehrenstein, C, Kleine-Tebbe, A, Griffin, JL, Orešič, M, Dietel, M, Denkert, C & Fiehn, O 2013, 'Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: Alterations in glutamine and beta-alanine metabolism', Journal of Proteomics, vol. 94, pp. 279-288. https://doi.org/10.1016/j.jprot.2013.10.002
Budczies, Jan ; Brockmöller, Scarlet F. ; Müller, Berit M. ; Barupal, Dinesh K. ; Richter-Ehrenstein, Christiane ; Kleine-Tebbe, Anke ; Griffin, Julian L. ; Orešič, Matej ; Dietel, Manfred ; Denkert, Carsten ; Fiehn, Oliver. / Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer : Alterations in glutamine and beta-alanine metabolism. In: Journal of Proteomics. 2013 ; Vol. 94. pp. 279-288.
@article{b1ec8efb140b448a9f8dd3bb37184c00,
title = "Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: Alterations in glutamine and beta-alanine metabolism",
abstract = "Molecular subtyping of breast cancer is necessary for therapy selection and mandatory for all breast cancer patients. Metabolic alterations are considered a hallmark of cancer and several metabolic drugs are currently being investigated in clinical trials. However, the dependence of metabolic alterations on breast cancer subtypes has not been investigated on -omics scale. Thus, 204 estrogen receptor positive (ER+) and 67 estrogen receptor negative (ER-) breast cancer tissues were investigated using GC-TOFMS based metabolomics. 19 metabolites were detected as altered in a predefined training set (2/3 of tumors) and could be validated in a predefined validation set (1/3 of tumors). The metabolite changes included increases in beta-alanine, 2-hydroyglutarate, glutamate, xanthine and decreases in glutamine in the ER- subtype. Beta-alanine demonstrated the strongest change between ER- and ER+ breast cancer (fold change = 2.4, p = 1.5E. -20). In a correlation analysis with genome-wide expression data in a subcohort of 154 tumors, we found a strong negative correlation (Spearman R = -0.62) between beta-alanine and 4-aminobutyrate aminotransferase (ABAT). Immunohistological analysis confirmed down-regulation of the ABAT protein in ER- breast cancer. In a Kaplan-Meier analysis of a large external expression data set, the ABAT transcript was demonstrated to be a positive prognostic marker for breast cancer (HR = 0.6, p=3.2E-15). Biological significance: It is well-known for more than a decade that breast cancer exhibits distinct gene expression patterns depending on the molecular subtype defined by estrogen receptor (ER) and HER2 status. Here, we show that breast cancer exhibits distinct metabolomics patterns depending on ER status. Our observation supports the current view of ER+ breast cancer and ER- breast as different diseases requiring different treatment strategies.Metabolic drugs for cancer including glutaminase inhibitors are currently under development and tested in clinical trials. We found glutamate enriched and glutamine reduced in ER- breast cancer compared to ER+ breast cancer and compared to normal breast tissues. Thus, metabolomics analysis highlights the ER- subtype as a preferential target for glutaminase inhibitors.For the first time, we report on a regulation of beta-alanine catabolism in cancer. In breast cancer, ABAT transcript expression was variable and correlated with ER status. Low ABAT transcript expression was associated with low ABAT protein expression and high beta-alanine concentration. In a large external microarray cohort, low ABAT expression shortened recurrence-free survival in breast cancer, ER+ breast cancer and ER- breast cancer.",
keywords = "ABAT, Beta-alanine, Breast cancer, GABA transaminase, Hormone receptor status, Metabolomics",
author = "Jan Budczies and Brockm{\"o}ller, {Scarlet F.} and M{\"u}ller, {Berit M.} and Barupal, {Dinesh K.} and Christiane Richter-Ehrenstein and Anke Kleine-Tebbe and Griffin, {Julian L.} and Matej Orešič and Manfred Dietel and Carsten Denkert and Oliver Fiehn",
year = "2013",
month = "12",
day = "6",
doi = "10.1016/j.jprot.2013.10.002",
language = "English (US)",
volume = "94",
pages = "279--288",
journal = "Journal of Proteomics",
issn = "1874-3919",
publisher = "Elsevier",

}

TY - JOUR

T1 - Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer

T2 - Alterations in glutamine and beta-alanine metabolism

AU - Budczies, Jan

AU - Brockmöller, Scarlet F.

AU - Müller, Berit M.

AU - Barupal, Dinesh K.

AU - Richter-Ehrenstein, Christiane

AU - Kleine-Tebbe, Anke

AU - Griffin, Julian L.

AU - Orešič, Matej

AU - Dietel, Manfred

AU - Denkert, Carsten

AU - Fiehn, Oliver

PY - 2013/12/6

Y1 - 2013/12/6

N2 - Molecular subtyping of breast cancer is necessary for therapy selection and mandatory for all breast cancer patients. Metabolic alterations are considered a hallmark of cancer and several metabolic drugs are currently being investigated in clinical trials. However, the dependence of metabolic alterations on breast cancer subtypes has not been investigated on -omics scale. Thus, 204 estrogen receptor positive (ER+) and 67 estrogen receptor negative (ER-) breast cancer tissues were investigated using GC-TOFMS based metabolomics. 19 metabolites were detected as altered in a predefined training set (2/3 of tumors) and could be validated in a predefined validation set (1/3 of tumors). The metabolite changes included increases in beta-alanine, 2-hydroyglutarate, glutamate, xanthine and decreases in glutamine in the ER- subtype. Beta-alanine demonstrated the strongest change between ER- and ER+ breast cancer (fold change = 2.4, p = 1.5E. -20). In a correlation analysis with genome-wide expression data in a subcohort of 154 tumors, we found a strong negative correlation (Spearman R = -0.62) between beta-alanine and 4-aminobutyrate aminotransferase (ABAT). Immunohistological analysis confirmed down-regulation of the ABAT protein in ER- breast cancer. In a Kaplan-Meier analysis of a large external expression data set, the ABAT transcript was demonstrated to be a positive prognostic marker for breast cancer (HR = 0.6, p=3.2E-15). Biological significance: It is well-known for more than a decade that breast cancer exhibits distinct gene expression patterns depending on the molecular subtype defined by estrogen receptor (ER) and HER2 status. Here, we show that breast cancer exhibits distinct metabolomics patterns depending on ER status. Our observation supports the current view of ER+ breast cancer and ER- breast as different diseases requiring different treatment strategies.Metabolic drugs for cancer including glutaminase inhibitors are currently under development and tested in clinical trials. We found glutamate enriched and glutamine reduced in ER- breast cancer compared to ER+ breast cancer and compared to normal breast tissues. Thus, metabolomics analysis highlights the ER- subtype as a preferential target for glutaminase inhibitors.For the first time, we report on a regulation of beta-alanine catabolism in cancer. In breast cancer, ABAT transcript expression was variable and correlated with ER status. Low ABAT transcript expression was associated with low ABAT protein expression and high beta-alanine concentration. In a large external microarray cohort, low ABAT expression shortened recurrence-free survival in breast cancer, ER+ breast cancer and ER- breast cancer.

AB - Molecular subtyping of breast cancer is necessary for therapy selection and mandatory for all breast cancer patients. Metabolic alterations are considered a hallmark of cancer and several metabolic drugs are currently being investigated in clinical trials. However, the dependence of metabolic alterations on breast cancer subtypes has not been investigated on -omics scale. Thus, 204 estrogen receptor positive (ER+) and 67 estrogen receptor negative (ER-) breast cancer tissues were investigated using GC-TOFMS based metabolomics. 19 metabolites were detected as altered in a predefined training set (2/3 of tumors) and could be validated in a predefined validation set (1/3 of tumors). The metabolite changes included increases in beta-alanine, 2-hydroyglutarate, glutamate, xanthine and decreases in glutamine in the ER- subtype. Beta-alanine demonstrated the strongest change between ER- and ER+ breast cancer (fold change = 2.4, p = 1.5E. -20). In a correlation analysis with genome-wide expression data in a subcohort of 154 tumors, we found a strong negative correlation (Spearman R = -0.62) between beta-alanine and 4-aminobutyrate aminotransferase (ABAT). Immunohistological analysis confirmed down-regulation of the ABAT protein in ER- breast cancer. In a Kaplan-Meier analysis of a large external expression data set, the ABAT transcript was demonstrated to be a positive prognostic marker for breast cancer (HR = 0.6, p=3.2E-15). Biological significance: It is well-known for more than a decade that breast cancer exhibits distinct gene expression patterns depending on the molecular subtype defined by estrogen receptor (ER) and HER2 status. Here, we show that breast cancer exhibits distinct metabolomics patterns depending on ER status. Our observation supports the current view of ER+ breast cancer and ER- breast as different diseases requiring different treatment strategies.Metabolic drugs for cancer including glutaminase inhibitors are currently under development and tested in clinical trials. We found glutamate enriched and glutamine reduced in ER- breast cancer compared to ER+ breast cancer and compared to normal breast tissues. Thus, metabolomics analysis highlights the ER- subtype as a preferential target for glutaminase inhibitors.For the first time, we report on a regulation of beta-alanine catabolism in cancer. In breast cancer, ABAT transcript expression was variable and correlated with ER status. Low ABAT transcript expression was associated with low ABAT protein expression and high beta-alanine concentration. In a large external microarray cohort, low ABAT expression shortened recurrence-free survival in breast cancer, ER+ breast cancer and ER- breast cancer.

KW - ABAT

KW - Beta-alanine

KW - Breast cancer

KW - GABA transaminase

KW - Hormone receptor status

KW - Metabolomics

UR - http://www.scopus.com/inward/record.url?scp=84886279046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886279046&partnerID=8YFLogxK

U2 - 10.1016/j.jprot.2013.10.002

DO - 10.1016/j.jprot.2013.10.002

M3 - Article

VL - 94

SP - 279

EP - 288

JO - Journal of Proteomics

JF - Journal of Proteomics

SN - 1874-3919

ER -